Other Infiltrative Cardiomyopathies e320ħ.7.1. Arrhythmogenic Right Ventricular Cardiomyopathy e312ħ.6.1. Treatment of Recurrent VA in Patients With NICM e310ħ.3. Primary Prevention of SCD in Patients With NICM e309ħ.2.3. Secondary Prevention of SCD in Patients With NICM e308ħ.2.2. Treatment and Prevention of Recurrent VA in Patients With Ischemic Heart Disease e306ħ.2.1. Primary Prevention of SCD in Patients With Ischemic Heart Disease e304ħ.1.3. Secondary Prevention of SCD in Patients With Ischemic Heart Disease e301ħ.1.2. Ongoing Management of VA and SCD Risk Related to Specific Disease States e301ħ.1.1. Surgery and Revascularization Procedures in Patients With Ischemic Heart Disease e296ĥ.5.1. VA in Patients With No Apparent Structural Heart Disease e296ĥ.5. Defibrillators for Treatment of VA and SCD e295ĥ.4.2. Preventing SCD With HF Medications e295ĥ.3. Nonantiarrhythmic Medications and Therapies e294ĥ.2. Medications With Prominent Sodium Channel Blockade e290ĥ.1.5. Therapies for Treatment or Prevention of VA e290ĥ.1.1. Invasive Cardiac Imaging: Cardiac Catheterization or CT Angiography e289Ĥ.3.2. Genetic Considerations in Arrhythmia Syndromes e288Ĥ.3.1. Ambulatory Electrocardiography e286Ĥ.2.6. 12-lead ECG and Exercise Testing e286Ĥ.2.2. History and Physical Examination e284Ĥ.2.1. General Evaluation of Patients With Documented or Suspected VA e284Ĥ.1. Cellular Mechanisms and Substrates e283Ĥ. Population Subgroups and Risk Prediction e282ģ.1. Sustained VT and VF Not Associated With ACS e281Ģ.2.2. Premature Ventricular Complexes and Nonsustained VT e279Ģ.1.3. Organization of the Writing Committee e276Ģ.1.1.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
December 2022
Categories |